Self-management Support in Cancer Pain

Overview

Pain is a prevalent and distressing symptom in patients with cancer, having an enormous impact on functioning and quality of life. Integration of patient self-management and professional care by means of care technology provides new opportunities in the outpatient setting. In this project a technology based and nurse delivered multicomponent self-management support intervention has been developed. Important components include monitoring, feedback, education, and nurse support. Following feasibility evaluation, the primary aim of this randomized controlled trial is to assess the effect of the intervention regarding pain intensity and quality of life as compared to care as usual. Secondary outcomes of the effect evaluation are self-efficacy, knowledge, anxiety and depression, and pain medication use. Besides, a cost-evaluation and summative process evaluation will be performed.

Full Title of Study: “Effects of a Multifaceted Teleguided Pain Care Program in Patients With Cancer Pain”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Supportive Care
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: June 2015

Interventions

  • Behavioral: Self-management support
    • The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients’ situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.

Arms, Groups and Cohorts

  • Experimental: Intervention group
    • Self-management support
  • No Intervention: Control group
    • Care as usual

Clinical Trial Outcome Measures

Primary Measures

  • Change in pain intensity (Brief Pain Inventory – Short Form (BPI-SF)
    • Time Frame: 12 weeks
    • As measured with the Brief Pain Inventory – Short Form (BPI-SF)
  • Change in cancer related quality of life (European Organisation for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-C30 version 3)
    • Time Frame: 12 weeks
    • As measured with the European Organisation for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-C30 version 3)

Secondary Measures

  • Change in self-efficacy (Chronic Pain Self-efficacy Scale (CPSS)
    • Time Frame: 12 weeks
    • As measured with the Chronic Pain Self-efficacy Scale (CPSS)
  • Change in knowledge about cancer pain (Pain Knowledge Questionnaire (PKQ)
    • Time Frame: 12 weeks
    • As measured with the Pain Knowledge Questionnaire (PKQ)
  • Change in anxiety and depression (Hospital Anxiety and Depression Scale (HADS)
    • Time Frame: 12 weeks
    • As measured with the Hospital Anxiety and Depression Scale (HADS)
  • Change in pain medication use (Brief Pain Inventory – Short Form (BPI-SF), a cost diary and a pharmacist’s overview)
    • Time Frame: 12 weeks
    • As measured with the Brief Pain Inventory – Short Form (BPI-SF), a cost diary and a pharmacist’s overview

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of cancer – Patients who are under (palliative) anti-tumour treatment in a day clinic or outpatient clinic, or patients who have no treatment options available anymore – Cancer (treatment related) pain > 2 weeks – Pain is defined as a patient reported pain score of 4 or more on a numerical rating scale (scale 0-10) – Living at home Exclusion Criteria:

  • Expected life expectancy < 3 months – Chronic non-cancer pain – Known cognitive impairments – Participation in other studies that interfere with this study – Not being able to read and understand the Dutch language – Reduced vision – Non-reachable by phone

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Maastricht University Medical Center
  • Collaborator
    • Atrium Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Laura Hochstenbach, MSc, +31 433881691, l.hochstenbach@maastrichtuniversity.nl

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.